Abelacimab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Target | Factor XI and its active form Factor XIa |
Clinical data | |
Other names | MAA868 |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | Intravenous |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG |
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of coagulation,[1] under development by Anthos Therapeutics.
Mechanism of action
It is anti-factor XI antibody.[1][2]
See also
References
- ^ a b Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, et al. (August 2021). "Abelacimab for Prevention of Venous Thromboembolism". The New England Journal of Medicine. 385 (7): 609–617. doi:10.1056/NEJMoa2105872. PMID 34297496. S2CID 236198598.
- ^ "Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)". Business Wire. 18 September 2023.
Categories:
- Articles with short description
- Short description is different from Wikidata
- Use dmy dates from November 2019
- Drugs with non-standard legal status
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Anticoagulants
- Monoclonal antibodies
- All stub articles
- Monoclonal antibody stubs
- Blood and blood forming organ drug stubs